Vanessa C Nicolete1,2, Sarah Frischmann2, Susana Barbosa1, Christopher L King2,3, Marcelo U Ferreira1. 1. Institute of Biomedical Sciences, University of São Paulo, Brazil. 2. Center for Global Health and Diseases, Case Western Reserve University School of Medicine. 3. Veteran Affairs Research Service, Louis B. Stokes VA Medical Center, Cleveland, Ohio.
Abstract
BACKGROUND: Antibodies to the cysteine-rich domain II of Plasmodium vivax Duffy binding protein (PvDBP) can inhibit binding of this parasite ligand to its receptor on red blood cells, the Duffy antigen/receptor for chemokines. These binding-inhibitory antibodies (BIAbs) also inhibit P. vivax invasion of reticulocytes in vitro. METHODS: To investigate whether naturally acquired anti-PvDBP antibodies are associated with reduced risk of clinical malaria in a population exposed to low levels of P. vivax transmission, we measured total levels of immunoglobulin G antibodies to 5 PvDBP variants and used a functional in vitro assay to quantify their binding-inhibitory activity in a cohort of 466 rural Amazonians followed up for up to 37 months. RESULTS: No association between total immunoglobulin G antibody responses to any PvDBP variant and risk of symptomatic, laboratory-confirmed vivax malaria was observed in this cohort. However, a Cox proportional hazards model, adjusted for age, sex, and genotype for the Duffy antigen/receptor for chemokines, showed a >40% decrease in the prospective risk of clinical vivax malaria in subjects with the strongest BIAb responses (upper and middle terciles). High BIAb responses were mostly PvDBP variant transcending and stable over time. CONCLUSIONS: Strong naturally acquired BIAb responses are associated with a reduced risk of clinical P. vivax malaria in rural Amazonians.
BACKGROUND: Antibodies to the cysteine-rich domain II of Plasmodium vivax Duffy binding protein (PvDBP) can inhibit binding of this parasite ligand to its receptor on red blood cells, the Duffy antigen/receptor for chemokines. These binding-inhibitory antibodies (BIAbs) also inhibit P. vivax invasion of reticulocytes in vitro. METHODS: To investigate whether naturally acquired anti-PvDBP antibodies are associated with reduced risk of clinical malaria in a population exposed to low levels of P. vivax transmission, we measured total levels of immunoglobulin G antibodies to 5 PvDBP variants and used a functional in vitro assay to quantify their binding-inhibitory activity in a cohort of 466 rural Amazonians followed up for up to 37 months. RESULTS: No association between total immunoglobulin G antibody responses to any PvDBP variant and risk of symptomatic, laboratory-confirmed vivax malaria was observed in this cohort. However, a Cox proportional hazards model, adjusted for age, sex, and genotype for the Duffy antigen/receptor for chemokines, showed a >40% decrease in the prospective risk of clinical vivax malaria in subjects with the strongest BIAb responses (upper and middle terciles). High BIAb responses were mostly PvDBP variant transcending and stable over time. CONCLUSIONS: Strong naturally acquired BIAb responses are associated with a reduced risk of clinical P. vivaxmalaria in rural Amazonians.
Authors: Fabiana P Alves; Rui R Durlacher; Maria J Menezes; Henrique Krieger; Luiz H Pereira Silva; Erney P Camargo Journal: Am J Trop Med Hyg Date: 2002-06 Impact factor: 2.345
Authors: J C Lima-Junior; T M Tran; E V S Meyer; B Singh; S G De-Simone; F Santos; C T Daniel-Ribeiro; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira Journal: Vaccine Date: 2008-12-02 Impact factor: 3.641
Authors: Danielle I Stanisic; Sarah Javati; Benson Kiniboro; Enmoore Lin; Jianlin Jiang; Balwan Singh; Esmeralda V S Meyer; Peter Siba; Cristian Koepfli; Ingrid Felger; Mary R Galinski; Ivo Mueller Journal: PLoS Negl Trop Dis Date: 2013-11-14
Authors: Arlene E Dent; Indu Malhotra; Xuelie Wang; Denise Babineau; Kee Thai Yeo; Timothy Anderson; Rhonda J Kimmel; Evelina Angov; David E Lanar; David Narum; Sheetij Dutta; Jack Richards; James G Beeson; Brendan S Crabb; Alan F Cowman; Toshihiro Horii; Eric Muchiri; Peter L Mungai; Christopher L King; James W Kazura Journal: Clin Vaccine Immunol Date: 2015-12-09
Authors: Lenore L Carias; Sebastien Dechavanne; Vanessa C Nicolete; Sokunthea Sreng; Seila Suon; Chanaki Amaratunga; Rick M Fairhurst; Celia Dechavanne; Samantha Barnes; Benoit Witkowski; Jean Popovici; Camille Roesch; Edwin Chen; Marcelo U Ferreira; Niraj H Tolia; John H Adams; Christopher L King Journal: J Immunol Date: 2019-04-03 Impact factor: 5.422
Authors: Francis B Ntumngia; Richard Thomson-Luque; Sandra Galusic; Gabriel Frato; Sarah Frischmann; David S Peabody; Bryce Chackerian; Marcelo U Ferreira; Christopher L King; John H Adams Journal: J Infect Dis Date: 2018-08-24 Impact factor: 5.226
Authors: Ruth O Payne; Sarah E Silk; Sean C Elias; Kathryn H Milne; Thomas A Rawlinson; David Llewellyn; A Rushdi Shakri; Jing Jin; Geneviève M Labbé; Nick J Edwards; Ian D Poulton; Rachel Roberts; Ryan Farid; Thomas Jørgensen; Daniel Gw Alanine; Simone C de Cassan; Matthew K Higgins; Thomas D Otto; James S McCarthy; Willem A de Jongh; Alfredo Nicosia; Sarah Moyle; Adrian Vs Hill; Eleanor Berrie; Chetan E Chitnis; Alison M Lawrie; Simon J Draper Journal: JCI Insight Date: 2017-06-15
Authors: Nora Céspedes; Connie S N Li Wai Suen; Cristian Koepfli; Camila T França; Ingrid Felger; Issa Nebie; Myriam Arévalo-Herrera; Ivo Mueller; Giampietro Corradin; Sócrates Herrera Journal: PLoS One Date: 2017-06-26 Impact factor: 3.240
Authors: Camilla V Pires; Jessica R S Alves; Barbara A S Lima; Ruth B Paula; Helena L Costa; Leticia M Torres; Taís N Sousa; Irene S Soares; Bruno A M Sanchez; Cor J F Fontes; Francis B Ntumngia; John H Adams; Flora S Kano; Luzia H Carvalho Journal: PLoS One Date: 2018-11-12 Impact factor: 3.240